Cara Therapeutics, Inc. (0HTC.L)

USD 5.33

(-0.22%)

Revenue Summary of Cara Therapeutics, Inc.

  • Cara Therapeutics, Inc.'s latest annual revenue in 2023 was 20.96 Million USD , down -49.92% from previous year.
  • Cara Therapeutics, Inc.'s latest quarterly revenue in 2024 Q2 was 991 Thousand USD , down -53.58% from previous quarter.
  • Cara Therapeutics, Inc. reported a annual revenue of 41.86 Million USD in annual revenue 2022, up 81.81% from previous year.
  • Cara Therapeutics, Inc. reported a annual revenue of 23.02 Million USD in annual revenue 2021, down -82.95% from previous year.
  • Cara Therapeutics, Inc. reported a quarterly revenue of 2.13 Million USD for 2024 Q1, down -28.93% from previous quarter.
  • Cara Therapeutics, Inc. reported a quarterly revenue of 4.86 Million USD for 2023 Q3, down -29.81% from previous quarter.

Annual Revenue Chart of Cara Therapeutics, Inc. (2023 - 2011)

Historical Annual Revenue of Cara Therapeutics, Inc. (2023 - 2011)

Year Revenue Revenue Growth
2023 20.96 Million USD -49.92%
2022 41.86 Million USD 81.81%
2021 23.02 Million USD -82.95%
2020 135.08 Million USD 579.28%
2019 19.88 Million USD 47.64%
2018 13.46 Million USD 1378.49%
2017 911 Thousand USD 959.3%
2016 86 Thousand USD -97.74%
2015 3.8 Million USD 19.7%
2014 3.17 Million USD -73.45%
2013 11.96 Million USD 905.38%
2012 1.19 Million USD 0.0%
2011 - USD 0.0%

Peer Revenue Comparison of Cara Therapeutics, Inc.

Name Revenue Revenue Difference
uniQure N.V. 15.84 Million USD -32.349%
Abeona Therapeutics Inc. 3.5 Million USD -499.086%
Aclaris Therapeutics, Inc. 31.24 Million USD 32.9%
Agios Pharmaceuticals, Inc. 26.82 Million USD 21.828%
Atara Biotherapeutics, Inc. 8.57 Million USD -144.582%
Imunon, Inc. - USD -Infinity%
Dynavax Technologies Corporation 232.28 Million USD 90.973%
Editas Medicine, Inc. 78.12 Million USD 73.16%
FibroGen, Inc. 147.75 Million USD 85.809%
Iovance Biotherapeutics, Inc. 1.18 Million USD -1663.499%
Kala Pharmaceuticals, Inc. - USD -Infinity%
Neurocrine Biosciences, Inc. 1.88 Billion USD 98.889%
Sarepta Therapeutics, Inc. 1.24 Billion USD 98.314%
Supernus Pharmaceuticals, Inc. 607.52 Million USD 96.549%
Verastem, Inc. - USD -Infinity%
Zoetis Inc. 8.54 Billion USD 99.755%
Vertex Pharmaceuticals Incorporated 9.86 Billion USD 99.788%
Sangamo Therapeutics, Inc. 176.23 Million USD 88.102%
Homology Medicines, Inc. -6.65 Million USD 415.261%
Nektar Therapeutics 90.12 Million USD 76.734%
Viking Therapeutics, Inc. - USD -Infinity%
Unity Biotechnology, Inc. - USD -Infinity%
Perrigo Company plc 4.65 Billion USD 99.55%
Esperion Therapeutics, Inc. 116.33 Million USD 81.976%
Walgreens Boots Alliance, Inc. 147.65 Billion USD 99.986%
Illumina, Inc. 4.5 Billion USD 99.534%
Thermo Fisher Scientific Inc. 42.85 Billion USD 99.951%
IQVIA Holdings Inc. 14.98 Billion USD 99.86%
Heron Therapeutics, Inc. 127.04 Million USD 83.495%
Waters Corporation 2.95 Billion USD 99.291%
Biogen Inc. 9.83 Billion USD 99.787%
Evolus, Inc. 202.08 Million USD 89.624%
Adicet Bio, Inc. - USD -Infinity%
bluebird bio, Inc. 29.49 Million USD 28.915%
Geron Corporation 237 Thousand USD -8747.257%
Alnylam Pharmaceuticals, Inc. 1.82 Billion USD 98.853%
Amicus Therapeutics, Inc. 399.35 Million USD 94.75%
Myriad Genetics, Inc. 678.4 Million USD 96.909%
Intellia Therapeutics, Inc. 36.27 Million USD 42.197%
Mettler-Toledo International Inc. 3.78 Billion USD 99.447%
Corbus Pharmaceuticals Holdings, Inc. - USD -Infinity%
BioMarin Pharmaceutical Inc. 2.41 Billion USD 99.133%
Regeneron Pharmaceuticals, Inc. 13.11 Billion USD 99.84%
Agilent Technologies, Inc. 6.83 Billion USD 99.693%
OPKO Health, Inc. 863.49 Million USD 97.572%
Exelixis, Inc. 1.83 Billion USD 98.854%
Corcept Therapeutics Incorporated 482.37 Million USD 95.653%
Anavex Life Sciences Corp. - USD -Infinity%
Axsome Therapeutics, Inc. 270.6 Million USD 92.251%
Ionis Pharmaceuticals, Inc. 787.64 Million USD 97.338%
Halozyme Therapeutics, Inc. 829.25 Million USD 97.471%
Blueprint Medicines Corporation 249.38 Million USD 91.592%
Insmed Incorporated 305.2 Million USD 93.13%
TG Therapeutics, Inc. 233.66 Million USD 91.026%
Incyte Corporation 3.69 Billion USD 99.433%
Emergent BioSolutions Inc. 1.04 Billion USD 98.002%